文献速递甲状腺疾病

年龄或性别与Graves病严重程度或治疗预后的关系

Does Age or Sex Relate to Severity or Treatment Prognosis in Graves' Disease?
PubMed 文献 · Thyroid · 2021-05-26

本研究回顾性分析了21,633例新诊断Graves病患者,评估年龄和性别与疾病严重程度及抗甲状腺药物治疗预后的关系。结果显示,20-39岁男性初始fT4显著高于女性,且游离甲状腺激素水平随年龄增长而下降;女性达到缓解的可能性高于男性(aHR=1.41),而年轻患者复发风险更高(每增加10岁,aHR=0.86),复发与性别无关。

要点

  • 20-39岁男性Graves病患者的初始甲状腺激素水平显著高于同年龄段女性。
  • 女性接受抗甲状腺药物治疗后达到缓解的可能性显著高于男性(aHR=1.41)。
  • 年龄每增加10岁,复发风险降低14%(aHR=0.86),复发与性别无关。

核心结论

  • Graves病甲亢严重程度在20-39岁男性中更高,且随年龄增长而下降。
  • 女性比男性更易达到缓解,年轻患者复发风险更高,复发与性别无关。

研究设计与样本

  • 回顾性研究,纳入2005年1月至2019年6月新诊断的Graves病患者,共21,633例(男性3954例,女性17,679例)。
  • 其中2009年1月至2010年12月诊断且随访至少12个月的患者纳入分析。
  • 患者按年龄分为9组,缓解定义为停用抗甲状腺药物后维持甲状腺功能正常状态超过1年。

主要发现

  • 初始fT3和fT4水平随年龄增长显著下降,性别分层后仍如此。
  • 20-39岁男性fT4显著高于女性。
  • 在2191例仅用抗甲状腺药物治疗的患者中,男性和女性达到缓解的中位时间分别为37.7个月和30.6个月。
  • Kaplan-Meier分析显示男性达到缓解的时间显著长于女性(p < 0.0001),年龄差异无统计学意义(p = 0.08)。
  • Cox比例风险模型显示女性缓解风险比男性高41%(aHR=1.41,95%CI 1.21-1.64),年龄每增加10岁复发风险降低14%(aHR=0.86,95%CI 0.78-0.94)。

关键数值与推荐

  • 缓解定义为停用抗甲状腺药物后维持甲状腺功能正常状态超过1年。
  • 女性相比男性的缓解调整风险比(aHR)为1.41(95%CI 1.21-1.64)。
  • 年龄每增加10岁的复发调整风险比(aHR)为0.86(95%CI 0.78-0.94)。

临床怎么用

  • 对于20-39岁男性Graves病患者,应关注其可能更高的甲亢严重程度。
  • 女性患者接受抗甲状腺药物治疗可能更易达到缓解,而年轻患者需警惕更高的复发风险。
  • 制定个体化治疗和随访策略时,应考虑年龄和性别对预后的影响。

局限性

  • 本研究为回顾性研究,可能存在选择偏倚和信息偏倚。
  • 仅纳入2009-2010年诊断且随访至少12个月的患者进行预后分析,样本量有限。
  • 未报告遗传因素等其他可能影响预后的变量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The prognosis of Graves' disease (GD) is reportedly related to sex, age, and genetic factors, although there is no consensus. The objective of this study was to investigate the relationship between severity and prognosis of GD and sex or age. Methods: Subjects were patients newly diagnosed with GD between January 2005 and June 2019, and medical records were retrospectively reviewed. Patients diagnosed between January 2009 and December 2010 and followed up for at least 12 months were enrolled. Patients were divided into nine age-stratified groups. Remission was defined as maintenance of a euthyroid state for more than one year after withdrawal of antithyroid drugs (ATDs). Results: Participants comprised 21,633 patients (3954 males, 17,679 females). Initial free triiodothyronine (fT3) and free thyroxine (fT4) levels significantly decreased with increasing age, including after sex stratification. fT4 was significantly higher in males than females aged 20-39 years. In 2191 patients treated with ATDs alone, median durations until remission were 37.7 and 30.6 months in males and females, respectively. Remission and recurrence were observed in 1391 patients (204 males, 1187 females) and 262 patients (37 males, 225 females), respectively. By Kaplan-Meier analyses, males required a significantly longer time to achieve remission than females (p < 0.0001), although there were no significant age-related differences (p = 0.08). Cox proportional hazard modeling showed a 41% higher hazard ratio (HR) for remission in females than males (adjusted HRs [aHR] confidence interval [CI] = 1.41 [1.21-1.64]), and each additional 10 years of age had a 14% lower rate of recurrence (age [per 10-year increase], aHR [CI] = 0.86 [0.78-0.94]); no significant relationship between recurrence rate and sex was identified. Conclusions: Severity of hyperthyroidism in GD was significantly higher in males in their 20s and 30s, declining with advancing age in both sexes. Females were more likely to achieve remission than males, and younger patients had a higher risk of recurrence, although recurrence was unrelated to sex.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Suzuki N, Noh JY, Yoshimura R, et al. Does Age or Sex Relate to Severity or Treatment Prognosis in Graves' Disease? Thyroid. 2021. PMID: 33882721. doi:10.1089/thy.2020.0881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。